| Primary |
| Drug Use For Unknown Indication |
31.6% |
| General Anaesthesia |
26.3% |
| Analgesic Therapy |
21.1% |
| Anaesthesia |
10.5% |
| Hypotonia |
5.3% |
| Muscle Relaxant Therapy |
5.3% |
|
| Off Label Use |
50.0% |
| Oxygen Saturation Decreased |
33.3% |
| Post Procedural Complication |
16.7% |
|
| Secondary |
| Maintenance Of Anaesthesia |
25.2% |
| General Anaesthesia |
22.8% |
| Induction Of Anaesthesia |
15.0% |
| Anaesthesia |
5.4% |
| Drug Use For Unknown Indication |
4.7% |
| Prophylaxis |
4.5% |
| Product Used For Unknown Indication |
4.2% |
| Induction And Maintenance Of Anaesthesia |
4.0% |
| Anaesthesia Procedure |
2.1% |
| Analgesia |
1.6% |
| Sedation |
1.6% |
| Surgery |
1.6% |
| Arteriospasm Coronary |
1.0% |
| Blood Pressure Decreased |
1.0% |
| Muscle Relaxant Therapy |
1.0% |
| Postoperative Analgesia |
1.0% |
| Colectomy |
0.9% |
| Hypotonia |
0.9% |
| Premedication |
0.9% |
| Anaesthesia Reversal |
0.7% |
|
| Post Procedural Complication |
24.4% |
| Ventricular Fibrillation |
8.1% |
| Rhabdomyolysis |
7.0% |
| Ventricular Tachycardia |
7.0% |
| Cardiac Arrest |
5.8% |
| Delayed Recovery From Anaesthesia |
5.8% |
| Procedural Complication |
5.8% |
| Stress Cardiomyopathy |
5.8% |
| Hyperthermia Malignant |
3.5% |
| Renal Impairment |
3.5% |
| Sedation |
3.5% |
| White Blood Cell Count Increased |
3.5% |
| Aspartate Aminotransferase Increased |
2.3% |
| Atrioventricular Block Complete |
2.3% |
| Grand Mal Convulsion |
2.3% |
| Nodal Rhythm |
2.3% |
| Pulseless Electrical Activity |
2.3% |
| Subcutaneous Emphysema |
2.3% |
| Abdominal Pain |
1.2% |
| Bronchospasm |
1.2% |
|
| Concomitant |
| Induction Of Anaesthesia |
24.2% |
| Maintenance Of Anaesthesia |
19.8% |
| General Anaesthesia |
8.0% |
| Product Used For Unknown Indication |
6.5% |
| Drug Use For Unknown Indication |
5.5% |
| Induction And Maintenance Of Anaesthesia |
5.4% |
| Anaesthesia |
5.2% |
| Epidural Anaesthesia |
3.2% |
| Analgesic Therapy |
2.9% |
| Anaesthesia Procedure |
2.4% |
| Vasodilatation |
2.2% |
| Retinal Detachment |
2.1% |
| Tumour Excision |
2.1% |
| Cardiac Disorder |
2.0% |
| Hypotonia |
1.9% |
| Neuromuscular Blockade Reversal |
1.5% |
| Hospitalisation |
1.3% |
| Infection Prophylaxis |
1.2% |
| Muscle Relaxant Therapy |
1.2% |
| Neuromuscular Blocking Therapy |
1.2% |
|
| Ventricular Tachycardia |
14.2% |
| Cardiac Arrest |
13.2% |
| Rhabdomyolysis |
12.3% |
| Anaphylactic Shock |
5.7% |
| Hyperthermia Malignant |
4.7% |
| Tachycardia |
4.7% |
| Arteriospasm Coronary |
3.8% |
| Cough |
3.8% |
| Hypotension |
3.8% |
| Oxygen Saturation Decreased |
3.8% |
| Stress Cardiomyopathy |
3.8% |
| Ventricular Fibrillation |
3.8% |
| Bradycardia |
2.8% |
| Crush Syndrome |
2.8% |
| Liver Function Test Abnormal |
2.8% |
| Nodal Rhythm |
2.8% |
| Post Procedural Haemorrhage |
2.8% |
| Sputum Retention |
2.8% |
| Type I Hypersensitivity |
2.8% |
| Urticaria |
2.8% |
|
| Interacting |
| General Anaesthesia |
31.3% |
| Atrial Fibrillation |
21.9% |
| Arrhythmia |
12.5% |
| Maintenance Of Anaesthesia |
9.4% |
| Osteomyelitis |
9.4% |
| Anaesthesia |
6.3% |
| Arrhythmia Prophylaxis |
6.3% |
| Neuromuscular Blocking Therapy |
3.1% |
|
| Ventricular Fibrillation |
100.0% |
|
